Alzheimer’s isn’t just a protein problem. Early on, the DNA inside neurons starts getting tired. Weak. Broken.
When both strands of that DNA ladder snap at once—a double-strand break—it’s trouble. The cell can die. It can go rogue. In patients with Alzheimer’s these breaks happen far more often than in healthy folks, pointing to them as a hidden driver of the disease symptoms.
We’ve only just started untangling how DNA damage and inflammation feed the beast.
A 2022 study showed us how: broken neurons in a mouse brain trigger an immune response. The brain’s resident defenders, microglia, light up like fireworks. Chronic microglia activation is central to Alzheimer’s progression. Scientists noted in 2020 that we could potentially “modulate at various points… to prevent or modify disease progression.”
Now, neuroscientists at King’s College London say they have a tool for the job. It’s already proven safe in healthy men. It passed Phase 1 trials. The name is KCL-286.
KCL-286 takes a familiar road. You take it by mouth. It crosses the blood-brain barrier easily. It wakes up a protein in the retinoic acid path to spur nerve growth.
It wasn’t born for dementia.
It was built for spinal cord injuries and nerve repair. Those tests are still ongoing. But the team saw another angle. Why not aim at the brain?
“This will dramatically cut down the traditional multiyear timeline required for new drug development.” — Jonathan Corcoran, King’s College London
Since the safety gate was already open, they didn’t need to start from scratch.
They grabbed Tg2576 mice—genetically tweaked to hoard amyloid-beta plaques, mimicking the human condition. Three mice got the KCL-280 injections three times a week. From 15 to 18 months of age. That’s the middle age of a mouse life, equivalent to the slow creep of symptoms in humans.
Others got fake injections. Controls stayed wild type. No mods.
At 18 months, they put the mice to sleep and looked at their brains under a microscope. They stained for proteins. For molecules. For signs of repair.
The difference was stark.
KCL-281 boosted the repair of those nasty double-strand breaks. How? By ramping up BRCA1.
You might know BRCA1 from cancer news. It suppresses tumors. It fixes broken DNA. In untreated Alzheimer’s model mice, BRCA1 usually plummets. A sign of system failure. But these specific mice were still fighting back. Trying, anyway.
The drug helped that fight win.
The researchers also noticed something else. The microglia settled down.
Calm. Less angry. Looking more like the cells of a healthy brain. Same for the astrocyte support cells.
Is this magic? Probably not. It’s targeted. It hits DNA damage and inflammation. Two pillars of the disease that stand tall early in the progression.
“Our findings demonstrate that KCL-285 not only targets DNA damage but also reduced inflammation… highlights its potential as a diseas-modifying therapy.”
The paper is out in FEBS Open Bio.
We don’t know yet if this works in people with full-blown dementia. We don’t know if the safety in young men holds for frail, elderly patients with complex histories.
The timeline is shorter now. Much shorter. But the path from mouse to man is still a narrow one.
